JP2011511634A - ガン幹細胞に関連する方法および組成物 - Google Patents

ガン幹細胞に関連する方法および組成物 Download PDF

Info

Publication number
JP2011511634A
JP2011511634A JP2010545021A JP2010545021A JP2011511634A JP 2011511634 A JP2011511634 A JP 2011511634A JP 2010545021 A JP2010545021 A JP 2010545021A JP 2010545021 A JP2010545021 A JP 2010545021A JP 2011511634 A JP2011511634 A JP 2011511634A
Authority
JP
Japan
Prior art keywords
cells
mir
mirna
cell
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010545021A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011511634A5 (cg-RX-API-DMAC10.html
Inventor
マイケル クラーク，
ヨウヘイ シモノ，
Original Assignee
ザ ボード オブ トラスティーズ オブ ザ リランド スタンフォード ジュニア ユニヴァーシティ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ ボード オブ トラスティーズ オブ ザ リランド スタンフォード ジュニア ユニヴァーシティ filed Critical ザ ボード オブ トラスティーズ オブ ザ リランド スタンフォード ジュニア ユニヴァーシティ
Publication of JP2011511634A publication Critical patent/JP2011511634A/ja
Publication of JP2011511634A5 publication Critical patent/JP2011511634A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2010545021A 2008-02-01 2009-01-30 ガン幹細胞に関連する方法および組成物 Pending JP2011511634A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2557408P 2008-02-01 2008-02-01
PCT/US2009/000593 WO2009097136A1 (en) 2008-02-01 2009-01-30 Methods and compositions relating to carcinoma stem cells

Publications (2)

Publication Number Publication Date
JP2011511634A true JP2011511634A (ja) 2011-04-14
JP2011511634A5 JP2011511634A5 (cg-RX-API-DMAC10.html) 2012-03-22

Family

ID=40913151

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010545021A Pending JP2011511634A (ja) 2008-02-01 2009-01-30 ガン幹細胞に関連する方法および組成物

Country Status (7)

Country Link
US (1) US20110021607A1 (cg-RX-API-DMAC10.html)
EP (1) EP2247750A4 (cg-RX-API-DMAC10.html)
JP (1) JP2011511634A (cg-RX-API-DMAC10.html)
CN (1) CN101981206A (cg-RX-API-DMAC10.html)
AU (1) AU2009209415A1 (cg-RX-API-DMAC10.html)
CA (1) CA2713469A1 (cg-RX-API-DMAC10.html)
WO (1) WO2009097136A1 (cg-RX-API-DMAC10.html)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2310507A4 (en) * 2008-07-08 2013-03-20 David Gladstone Inst METHOD AND COMPOSITIONS FOR ANGIOGENIC MODULATION
JP2012507300A (ja) 2008-10-30 2012-03-29 カリス ライフ サイエンシズ ルクセンブルク ホールディングス Ｒｎａパターンを評価する方法
EP2350320A4 (en) 2008-11-12 2012-11-14 Caris Life Sciences Luxembourg Holdings METHOD AND SYSTEMS FOR USE OF EXOSOMES FOR THE DETERMINATION OF PHENOTYPES
EP2316972A1 (en) * 2009-10-29 2011-05-04 Deutsches Krebsforschungszentrum Circulating miRNAs as non-invasive markers for diagnosis and staging in prostate cancer
AU2011223789A1 (en) 2010-03-01 2012-09-20 Caris Life Sciences Switzerland Holdings Gmbh Biomarkers for theranostics
KR20130043104A (ko) 2010-04-06 2013-04-29 카리스 라이프 사이언스 룩셈부르크 홀딩스 질병용 순환 생물학적 지표들
EP3228629A1 (en) * 2010-06-16 2017-10-11 Minerva Biotechnologies Corporation Reprogramming cancer cells
WO2012065027A2 (en) 2010-11-11 2012-05-18 University Of Miami Compositions, kits and methods for treatment of cardiovascular, immunological, and inflammatory diseases
US8895509B2 (en) 2010-11-23 2014-11-25 Georgia Tech Research Corporation MIR-200 family induces mesenchymal-to-epithelial transition (MET) in ovarian cancer cells
TW201239097A (en) * 2010-12-17 2012-10-01 Sanofi Sa MiRNAs in joint disease
CN102168085A (zh) * 2011-01-31 2011-08-31 中山大学肿瘤防治中心 抑制miR-130b基因表达的siRNA和表达载体及其在制备提高肝癌治疗效果的药物中的应用
EP4086338A1 (en) 2011-03-17 2022-11-09 Minerva Biotechnologies Corporation Method for making pluripotent stem cells
WO2013009705A2 (en) * 2011-07-09 2013-01-17 The Trustees Of Columbia University In The City Of New York Biomarkers, methods, and compositions for inhibiting a multi-cancer mesenchymal transition mechanism
WO2013048345A1 (en) * 2011-09-28 2013-04-04 Agency For Science, Technology And Research Methods and pharmaceutical compositions for treating cancer
WO2013119923A1 (en) * 2012-02-09 2013-08-15 The Regents Of The University Of Michigan Different states of cancer stem cells
WO2013190091A1 (en) * 2012-06-21 2013-12-27 Ruprecht-Karls-Universität Heidelberg CIRCULATING miRNAs AS MARKERS FOR BREAST CANCER
US20150344961A1 (en) * 2012-09-11 2015-12-03 New York University Sera Based miRNAs as Non-Invasive Biomarkers in Melanoma
CN104415351A (zh) * 2013-09-11 2015-03-18 中国人民解放军第二军医大学东方肝胆外科医院 MicroRNA-429在制备抗肝癌药物中的应用
CN103834692B (zh) * 2014-02-27 2016-03-30 南京医科大学 一种用于表达lncRNA的慢病毒载体及其应用
US9631194B2 (en) * 2014-04-04 2017-04-25 Beth Israel Deaconess Medical Center Methods and compositions for use in treatment of FOXP2-related cancers
CN104513852B (zh) * 2014-06-13 2016-08-24 南通大学附属医院 miRNAs在胃癌干细胞中表达谱的分析方法
CN107921147B (zh) 2015-05-05 2021-12-24 江苏命码生物科技有限公司 一种新的前体miRNA及其在肿瘤治疗中的应用
WO2017009837A1 (en) 2015-07-15 2017-01-19 Ramot At Tel Aviv University Ltd. Micro-rna for the treatment of malignant solid tumors and metastasis
WO2017207623A1 (en) * 2016-05-31 2017-12-07 Université de Lausanne Mirna as biomarkers and regulators of cancer stem cells
WO2018071154A1 (en) * 2016-10-10 2018-04-19 Tsai Kun Chih A novel invadopodia-specific marker of invasive cancer stem cells and the use thereof
US10767164B2 (en) 2017-03-30 2020-09-08 The Research Foundation For The State University Of New York Microenvironments for self-assembly of islet organoids from stem cells differentiation
CN107236749A (zh) * 2017-06-07 2017-10-10 汕头大学医学院附属肿瘤医院 一种光学分子成像报告基因及其用途
CN107858427B (zh) * 2017-10-24 2021-03-02 昆明理工大学 miR-429在制备乳腺癌诊断和检测试剂盒中的应用
US20220275455A1 (en) * 2019-07-08 2022-09-01 Preferred Networks, Inc. Data processing and classification for determining a likelihood score for breast disease
KR102414106B1 (ko) * 2020-03-12 2022-06-29 (주) 바이오인프라생명과학 유방암 진단용 다중 바이오마커 및 이의 용도
WO2021188894A2 (en) * 2020-03-20 2021-09-23 University Of Massachusetts Micrornas for prevention of clinical venous thromboembolic disease

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007081720A2 (en) * 2006-01-05 2007-07-19 The Ohio State University Research Foundation Microrna-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer
WO2008095096A2 (en) * 2007-01-31 2008-08-07 Immune Disease Institute Let-7 microrna and mimetics thereof as therapeutics for cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5707829A (en) * 1995-08-11 1998-01-13 Genetics Institute, Inc. DNA sequences and secreted proteins encoded thereby
US20100179213A1 (en) * 2008-11-11 2010-07-15 Mirna Therapeutics, Inc. Methods and Compositions Involving miRNAs In Cancer Stem Cells

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007081720A2 (en) * 2006-01-05 2007-07-19 The Ohio State University Research Foundation Microrna-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer
WO2008095096A2 (en) * 2007-01-31 2008-08-07 Immune Disease Institute Let-7 microrna and mimetics thereof as therapeutics for cancer

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
JPN6013048828; ＹＵ，　Ｆ．　ｅｔ　ａｌ．: '"ｌｅｔ-７　ｒｅｇｕｌａｔｅｓ　ｓｅｌｆ　ｒｅｎｅｗａｌ　ａｎｄ　ｔｕｍｏｒｉｇｅｎｉｃｉｔｙ　ｏｆ　ｂｒｅａｓｔ　ｃａｎｃｅｒ　ｃｅｌｌｓ．"' ＣＥＬＬ Ｖｏｌ．１３１，　Ｎｏ．６, 20071214, Ｐ．１１０９-１１２３ *
JPN6013048830; ＨＡＴＦＩＥＬＤ，　Ｓ．　ｅｔ　ａｌ．: '"ｍｉｃｒｏＲＮＡ　ａｎｄ　ｓｔｅｍ　ｃｅｌｌ　ｆｕｎｃｔｉｏｎ．"' ＣＥＬＬ　ＡＮＤ　ＴＩＳＳＵＥ　ＲＥＳＥＡＲＣＨ Ｖｏｌ．３３１，　Ｎｏ．１, 200801, Ｐ．５７-６６ *
JPN6013048833; ＳＴＥＮＶＡＮＧ，　Ｊ．　ｅｔ　ａｌ．: '"Ｔｈｅ　ｕｔｉｌｉｔｙ　ｏｆ　ＬＮＡ　ｉｎ　ｍｉｃｒｏＲＮＡ-ｂａｓｅｄ　ｃａｎｃｅｒ　ｄｉａｇｎｏｓｔｉｃｓ　ａｎｄ　ｔｈｅｒａｐｅｕｔｉｃｓ．"' ＳＥＭＩＮＡＲＳ　ＩＮ　ＣＡＮＣＥＲ　ＢＩＯＬＯＧＹ Ｖｏｌ．１８，　Ｎｏ．２, 2008, Ｐ．８９-１０２ *
JPN6013048835; ＳＥＭＰＥＲＥ，　Ｌ．Ｆ．　ｅｔ　ａｌ．: '"Ａｌｔｅｒｅｄ　ＭｉｃｒｏＲＮＡ　ｅｘｐｒｅｓｓｉｏｎ　ｃｏｎｆｉｎｅｄ　ｔｏ　ｓｐｅｃｉｆｉｃ　ｅｐｉｔｈｅｌｉａｌ　ｃｅｌｌ　ｓｕｂｐｏｐｕｌａｔｉｏｎｓ　ｉｎ　ｂｒｅａｓｔ　ｃａｎｃｅｒ．"' ＣＡＮＣＥＲ　ＲＥＳＥＡＲＣＨ Ｖｏｌ．６７，　Ｎｏ．２４, 20071215, Ｐ．１１６１２-１１６２０ *
JPN6013048837; ＸＩＡ，　Ｈ．Ｐ．: '"Ｇｒｅａｔ　Ｐｏｔｅｎｔｉａｌ　ｏｆ　ＭｉｃｒｏＲＮＡ　ｉｎ　Ｃａｎｃｅｒ　Ｓｔｅｍ　Ｃｅｌｌ．"' ＪＯＵＲＮＡＬ　ＯＦ　ＣＡＮＣＥＲ　ＭＯＬＥＣＵＬＥＳ Ｖｏｌ．４，　Ｎｏ．３, 2008, Ｐ．７９-８９ *

Also Published As

Publication number Publication date
CN101981206A (zh) 2011-02-23
WO2009097136A1 (en) 2009-08-06
EP2247750A1 (en) 2010-11-10
CA2713469A1 (en) 2009-08-06
EP2247750A4 (en) 2011-10-26
US20110021607A1 (en) 2011-01-27
AU2009209415A1 (en) 2009-08-06

Similar Documents

Publication Publication Date Title
US20110021607A1 (en) Methods and Compositions Relating to Carcinoma Stem Cells
Jin et al. RETRACTED ARTICLE: m6A mRNA methylation initiated by METTL3 directly promotes YAP translation and increases YAP activity by regulating the MALAT1-miR-1914-3p-YAP axis to induce NSCLC drug resistance and metastasis
JP6912538B2 (ja) 血中循環腫瘍細胞に関する方法およびアッセイ
Wu et al. CircIRAK3 sponges miR-3607 to facilitate breast cancer metastasis
Zhang et al. microRNA-21 promotes tumor proliferation and invasion in gastric cancer by targeting PTEN
Wu et al. Long noncoding RNA MALAT1: insights into its biogenesis and implications in human disease
Zhang et al. miR-125b is methylated and functions as a tumor suppressor by regulating the ETS1 proto-oncogene in human invasive breast cancer
Xia et al. MicroRNA‐216a/217‐induced epithelial‐mesenchymal transition targets PTEN and SMAD7 to promote drug resistance and recurrence of liver cancer
Parikh et al. microRNA-181a has a critical role in ovarian cancer progression through the regulation of the epithelial–mesenchymal transition
Zhou et al. MicroRNA-21 regulates the migration and invasion of a stem-like population in hepatocellular carcinoma
Liu et al. Distinct microRNA expression profiles in prostate cancer stem/progenitor cells and tumor-suppressive functions of let-7
CN102007223B (zh) 用于胃癌的诊断、预后和治疗的基于微rna的方法和组合物
JP5931050B2 (ja) ｍｉＲ−１５５によるミスマッチ修復およびゲノム安定性の調節に関連する材料および方法
Xiao et al. MiR-1 downregulation correlates with poor survival in clear cell renal cell carcinoma where it interferes with cell cycle regulation and metastasis
Zhang et al. piR-001773 and piR-017184 promote prostate cancer progression by interacting with PCDH9
Qi et al. Targeting the Wnt-regulatory protein CTNNBIP1 by microRNA-214 enhances the stemness and self-renewal of cancer stem-like cells in lung adenocarcinomas
Zhang et al. HOXA5 indicates poor prognosis and suppresses cell proliferation by regulating p21 expression in non small cell lung cancer
Cheng et al. miR-144-3p serves as a tumor suppressor by targeting FZD7 and predicts the prognosis of human glioblastoma.
JP5931897B2 (ja) マイクロｒｎａ−２１、ミスマッチ修復および結腸直腸癌に関連する物質および方法
Ge et al. RNA demethylase ALKBH5 suppresses tumorigenesis via inhibiting proliferation and invasion and promoting CD8+ T cell infiltration in colorectal cancer
Li et al. DDX11-AS1exacerbates bladder cancer progression by enhancing CDK6 expression via suppressing miR-499b-5p
Bharambe et al. Downregulation of miR-204 expression defines a highly aggressive subset of Group 3/Group 4 medulloblastomas
de Boer et al. Targeting PLK1 as a novel chemopreventive approach to eradicate preneoplastic mucosal changes in the head and neck
Zhang et al. RETRACTED ARTICLE: microRNA-877 inhibits malignant progression of colorectal cancer by directly targeting MTDH and regulating the PTEN/Akt pathway
Nakayama et al. Biological role and prognostic significance of NAC1 in ovarian cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120130

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130117

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131001

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140106

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140801